This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (163)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Alert me on articles by topic

Geethanjali Dornadula, PhD; Hui Zhang, MD, PhD; Bonnie VanUitert, MD; John Stern, MD; Lawrence Livornese, Jr, MD; Mark J. Ingerman, MD; James Witek, MD; Richard J. Kedanis, BA; Jaan Natkin, MD; Joseph DeSimone, MD; Roger J. Pomerantz, MD

JAMA. 1999;282:1627-1632.

Context  Despite suppressive treatment with highly active antiretroviral therapy (HAART), replication-competent virus can still be isolated from peripheral blood mononuclear cells and genital cells of many individuals receiving suppressive HAART.

Objective  To determine whether free virion RNA can be detected in the blood plasma and/or genital tract fluids from patients receiving suppressive HAART.

Design  Prospective cohort study conducted from November 1998 to May 1999.

Setting  Academic medical center.

Patients  Human immunodeficiency virus 1–infected individuals (20 men and 2 women) shown in our laboratories to have fewer than 50 copies/mL of HIV-1 RNA in peripheral blood plasma while taking suppressive HAART.

Main Outcome Measures  Free virion RNA levels in peripheral blood plasma and genital fluids, quantified using an ultrasensitive reverse transcriptase polymerase chain reaction able to quantify cell-free virion RNA to a lower limit of 5 copies/mL and qualitatively detect viral RNA below this level.

Results  In all 22 patients, residual viral RNA could be detected in the peripheral blood plasma (mean level, 17 copies/mL). The presence of viral RNA suggests that ongoing viral replication is occurring, albeit at low levels, in each patient evaluated. Viral RNA levels were lower in most patients' genital fluids compared with blood plasma and in 12 patients were undetectable.

Conclusions  These data suggest that low-level replication of HIV-1 in patients taking suppressive HAART may be demonstrated not only in peripheral blood mononuclear cells but also in peripheral plasma as cell-free virion RNA. Complete ablation of viral replication may require intensification of antiretroviral therapies beyond standard suppressive HAART.

Author Affiliations: The Dorrance H. Hamilton Laboratories, Center for Human Virology, Division of Infectious Diseases, Department of Medicine, Jefferson Medical College, Thomas Jefferson University (Drs Dornadula, Zhang, VanUitert, Livornese, Ingerman, Natkin, DeSimone, and Pomerantz and Mr Kedanis), Pennsylvania Hospital (Dr Stern), and MCP-Hahnemann University, Partnership Comprehensive Care (Dr Witek), Philadelphia, Pa.

RELATED LETTER

Residual HIV-1 RNA After Highly Active Antiretroviral Therapy
Macaulay A. C. Onuigbo, Roger J. Pomerantz, Hui Zhang, and Geetha Dornadula
JAMA. 2000;283(9):1138-1139.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Discontinuation of Anticytomegalovirus Therapy in Patients With HIV Infection and Cytomegalovirus Retinitis
Scott M. Whitcup, Eric Fortin, Anne S. Lindblad, Paul Griffiths, Julia A. Metcalf, Michael R. Robinson, Jody Manischewitz, Barbara Baird, Cheryl Perry, I. Michael Kidd, Tamara Vrabec, Richard T. Davey, Jr, Judith Falloon, Robert E. Walker, Joseph A. Kovacs, H. Clifford Lane, Robert B. Nussenblatt, Janine Smith, Henry Masur, and Michael A. Polis
JAMA. 1999;282(17):1633-1637.
ABSTRACT | FULL TEXT  

Exploring the Benefits and Limits of Highly Active Antiretroviral Therapy
Richard D'Aquila and Bruce Walker
JAMA. 1999;282(17):1668-1669.
EXTRACT | FULL TEXT  

November 3, 1999
JAMA. 1999;282(17):1689-1690.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle
Proc. Natl. Acad. Sci. USA 2008;105:4832-4837.
 

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Palmer et al.
Proc. Natl. Acad. Sci. USA 2008;105:3879-3884.
ABSTRACT | FULL TEXT  

Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome
Garcia-Gasco et al.
J Antimicrob Chemother 2008;61:699-704.
ABSTRACT | FULL TEXT  

Novel Pathway for Induction of Latent Virus from Resting CD4+ T Cells in the Simian Immunodeficiency Virus/Macaque Model of Human Immunodeficiency Virus Type 1 Latency
Shen et al.
J. Virol. 2007;81:1660-1670.
ABSTRACT | FULL TEXT  

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Gulick et al.
JAMA 2006;296:769-781.
ABSTRACT | FULL TEXT  

Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells.
Bailey et al.
J. Virol. 2006;80:6441-6457.
ABSTRACT | FULL TEXT  

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.
Bailey et al.
J. Virol. 2006;80:4758-4770.
ABSTRACT | FULL TEXT  

Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus
Tobin et al.
J. Virol. 2005;79:9625-9634.
ABSTRACT | FULL TEXT  

A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients
Monie et al.
J. Virol. 2005;79:5185-5202.
ABSTRACT | FULL TEXT  

In Vivo Evidence for Instability of Episomal Human Immunodeficiency Virus Type 1 cDNA
Sharkey et al.
J. Virol. 2005;79:5203-5210.
ABSTRACT | FULL TEXT  

Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART
Nettles et al.
JAMA 2005;293:817-829.
ABSTRACT | FULL TEXT  

Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection
Di Mascio et al.
J. Virol. 2004;78:10566-10573.
ABSTRACT | FULL TEXT  

A long-term latent reservoir for HIV-1: discovery and clinical implications
Siliciano and Siliciano
J Antimicrob Chemother 2004;54:6-9.
ABSTRACT | FULL TEXT  

P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy
Sankatsing et al.
Antimicrob. Agents Chemother. 2004;48:1073-1081.
FULL TEXT  

Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads
Persaud et al.
J. Virol. 2004;78:968-979.
ABSTRACT | FULL TEXT  

Viral Blip Dynamics during Highly Active Antiretroviral Therapy
Di Mascio et al.
J. Virol. 2003;77:12165-12172.
ABSTRACT | FULL TEXT  

Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years
Havlir et al.
J. Virol. 2003;77:11212-11219.
ABSTRACT | FULL TEXT  

New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma
Palmer et al.
J. Clin. Microbiol. 2003;41:4531-4536.
ABSTRACT | FULL TEXT  

Multiple Viral Genetic Analyses Detect Low-Level Human Immunodeficiency Virus Type 1 Replication during Effective Highly Active Antiretroviral Therapy
Frenkel et al.
J. Virol. 2003;77:5721-5730.
ABSTRACT | FULL TEXT  

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: Intrinsic stability predicts lifelong persistence
Strain et al.
Proc. Natl. Acad. Sci. USA 2003;100:4819-4824.
ABSTRACT | FULL TEXT  

Latency in Human Immunodeficiency Virus Type 1 Infection: No Easy Answers
Persaud et al.
J. Virol. 2003;77:1659-1665.
FULL TEXT  

In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months
Di Mascio et al.
J. Virol. 2003;77:2271-2275.
ABSTRACT | FULL TEXT  

The Significance of HIV Viral Load Assay Precision: A Review of the Package Insert Specifications of Two Commercial Kits
Chernoff
J Int Assoc Physicians AIDS Care (Chic Ill) 2002;1:134-140.
ABSTRACT  

Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure
Ruff et al.
J. Virol. 2002;76:9481-9492.
ABSTRACT | FULL TEXT  

Semen alterations in HIV-1 infected men
Dulioust et al.
Hum Reprod 2002;17:2112-2118.
ABSTRACT | FULL TEXT  

Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy
Valentin et al.
Proc. Natl. Acad. Sci. USA 2002;99:7015-7020.
ABSTRACT | FULL TEXT  

Intrinsic Stability of Episomal Circles Formed during Human Immunodeficiency Virus Type 1 Replication
Pierson et al.
J. Virol. 2002;76:4138-4144.
ABSTRACT | FULL TEXT  

Both R5 and X4 Human Immunodeficiency Virus Type 1 Variants Persist during Prolonged Therapy with Five Antiretroviral Drugs
van Rij et al.
J. Virol. 2002;76:3054-3058.
ABSTRACT | FULL TEXT  

Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14+ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy
Zhu et al.
J. Virol. 2002;76:707-716.
ABSTRACT | FULL TEXT  

Residual Viral Replication during Antiretroviral Therapy Boosts Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses in Subjects Treated Early after Infection
Ortiz et al.
J. Virol. 2002;76:411-415.
ABSTRACT | FULL TEXT  

Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART
Kulkosky et al.
Blood 2001;98:3006-3015.
ABSTRACT | FULL TEXT  

Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy
Havlir et al.
JAMA 2001;286:171-179.
ABSTRACT | FULL TEXT  

HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy
Hermankova et al.
JAMA 2001;286:196-207.
ABSTRACT | FULL TEXT  

Persistence of Infectious HIV on Follicular Dendritic Cells
Smith et al.
J. Immunol. 2001;166:690-696.
ABSTRACT | FULL TEXT  

Performance Characteristics of the QUANTIPLEX HIV-1 RNA 3.0 Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma
Erice et al.
J. Clin. Microbiol. 2000;38:2837-2845.
ABSTRACT | FULL TEXT  

Treatment-Induced Decline of Human Immunodeficiency Virus-1 p24 and HIV-1 RNA in Lymphoid Tissue of Patients with Early Human Immunodeficiency Virus-1 Infection
Kuster et al.
Am. J. Pathol. 2000;156:1973-1986.
ABSTRACT | FULL TEXT  

Residual HIV-1 RNA After Highly Active Antiretroviral Therapy
Onuigbo et al.
JAMA 2000;283:1138-1139.
FULL TEXT  

Residual HIV Replication Despite Potent Antiretroviral Therapy: More Evidence
JWatch Infect. Diseases 2000;2000:14-14.
FULL TEXT  

Ultra-"Ultrasensitive" Viral-Load Assays
AIDS Clin Care 2000;2000:5-5.
FULL TEXT  

""Undetectable"" HIV RNA Level Does Not Mean Zero
JWatch General 1999;1999:2-2.
FULL TEXT  

Exploring the Benefits and Limits of Highly Active Antiretroviral Therapy
D'Aquila and Walker
JAMA 1999;282:1668-1669.
FULL TEXT  

Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans
Igarashi et al.
Proc. Natl. Acad. Sci. USA 2001;98:658-663.
ABSTRACT | FULL TEXT